Venrock Healthcare Capital Partners III, L.P.

Filings by Venrock Healthcare Capital Partners III, L.P. span 5 companies, the busiest being KalVista Pharmaceuticals, Inc., Altimmune, Inc. and Cogent Biosciences, Inc. The record holds 41 filings, for trades running from 13 December 2019 to 25 March 2026.

Market trades split into 39 purchases (€50.5M) and 1 sale (€2.5M). Purchases outweigh sales by €47.9M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. In 2026 alone, the filings show no purchases and 1 sale.

Half of the purchases are above €456k and half below. Clusters matter here: 1 out of 25 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. After 11 purchases with a full 90-day history, the hit rate stands at 73% and the median 90-day move at +96.3%. They describe history only and say nothing certain about the share price ahead.

The record was last updated on 27 March 2026 with an open-market sale (€2.5M) in KalVista Pharmaceuticals, Inc. The clock since the last published purchase (11 April 2025) now reads 561 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.